Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 8/20 | 0.64 |
| ▸ | MMP8 | P22894 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | MMP1 | P03956 | 5/20 | 0.60 |
| ▸ | PKM | P14618 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10570690 | 0.89 | MMP13 (0.70) | MMP13MMP8HTTNPSR1MMP1 | |
| SCHEMBL10569165 | 0.86 | MMP13 (0.66) | MMP13MMP8HTTNPSR1MMP1 | |
| SCHEMBL4195258 | 0.82 | MMP13 (0.66) | MMP13MMP8HTTNPSR1MMP1 | |
| SCHEMBL6379006 | 0.81 | MMP13 (0.64) | MMP13MMP8HTTNPSR1MMP1 | |
| SCHEMBL7212113 | 0.81 | MMP13 (0.80) | MMP13MMP8HTTNPSR1MMP1 | |
| SCHEMBL4190555 | 0.81 | HTT (0.67) | MMP13MMP8HTTNPSR1MMP1 | |
| SCHEMBL7033006 | 0.80 | MMP13 (0.42) | MMP13MMP8HTTNPSR1MMP1 | |
| SCHEMBL6708168 | 0.79 | PKM (0.64) | MMP13MMP8HTTNPSR1MMP1 | |
| SCHEMBL3250372 | 0.79 | PKM (0.64) | MMP13MMP8HTTNPSR1MMP1 | |
| SCHEMBL20054093 | 0.79 | MMP13 (0.72) | MMP13MMP8HTTNPSR1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084470-B2 | Substituted nicotinamide compounds and uses thereof | GRUENENTHAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20090076086-A1 | SUBSTITUTED NICOTINAMIDE COMPOUNDS AND USES THEREOF | GRUENENTHAL GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| EP-0841323-B1 | Method for producing arylvinylsulfone | SUMITOMO CHEMICAL CO (JP) | 2003-03-05 | — | — | EP | disclosed |
| US-5902905-A | Method for producing arylvinylsulfone | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-05-11 | — | — | US | disclosed |
| EP-0841323-A2 | Method for producing arylvinylsulfone | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1998-05-13 | — | — | EP | disclosed |
| US-4562138-A | Nitrogen-containing heterocyclic blocked mercapto development inhibitors | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1985-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076086-A1 | SUBSTITUTED NICOTINAMIDE COMPOUNDS AND USES THEREOF | NNT, NAMPT, NADK | MMP13 1876/4885MMP8 1081/4885HTT 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.